NuVision Biotherapies Limited, a UK-based regenerative medicine company, and University of Tampere, Regea Cell and Tissue Centre, a Finnish clinical tissue bank, have announced the signing of a strategic partnership to distribute the sight saving and wound care regenerative therapy, Omnigen, throughout Finland. The partnership is NuVision’s first distribution outlet for clinical application in mainland EU.

Through this agreement, Regea will act as the exclusive distributor for the Omnigen product range to hospitals in Finland, with NuVision providing expert technical, scientific and clinical support.

Dr Andrew Hopkinson, founder and CEO of NuVision, said: “Clinicians have found Omnigen to be extremely convenient, easy to use, and effective in the treatment of ocular surface disorders. Through this partnership we will widen access to Omnigen across Finland, which is our first step into the European clinical market. NuVision has partnered with Regea to provide widespread access to Omnigen for Ophthalmology departments and patients across Finland. Since our launch last year, we have already demonstrated significant successes in NHS, private hospitals and veterinary hospitals in the UK, using Omnigen to help treat sight destroying conditions to restore patients vision. We are excited to be working with Regea who share our values of responsive and compassionate patient care. Together, we look forward to offering this groundbreaking regenerative therapy and high quality personal service to every ophthalmic surgeon in Finland”.

Peter Dines, Investment Director and Head of Life Sciences & Biosciences at Mercia Fund Management said “I am delighted to see NuVision’s continued clinical progression within the global life sciences sector, securing a key partnership with Regea. This new collaboration is a positive step towards increasing availability of its innovative technology, Omnigen, and places the company in a strong position for future international collaborations to help save the sight of patients globally.”